Inactivated Newcastle disease virus vaccine

Scientists involved : Dr. V.D. Padmanaban, Dr. K. Kumanan, Dr. K.Nachimuthu and  Dr. Daniel Joy Chandran 

Product Technology      

The vaccine is prepared using BHK21 adapted velogenic Newcastle disease virus. The vaccine seed virus has been passaged 41 times in BHK21 cells. The following is the flow chart for vaccine production - Propagation of seed virus in BHK21 cells in fermentors

• Harvesting the vaccine virus.
• Concentration of the vaccine virus using vaccine concentrator.
• Inactivation of the vaccine virus using formalin.
• Mixing the vaccine virus with Aluminium Hydroxide gel.
• Bottling and labeling, Sterility, Safety and Potency testing

Product Presentation 

As 50 or 100 doses vials

Product Utility 

All the currently available vaccines are being produced in embryonated chicken eggs and internationally it is advised to use Specific Pathogen Free embryos (SPF) for vaccine production. However the use of SPF eggs for vaccine production is likely to increase the cost of vaccine at least 30 times more than the ordinary embryos and further SPF eggs are not freely available in this country currently. The current vaccine has been adapted to BHK21 cellline, a mammalian cellline, which will not permit adventious poultry pathogens. Moreover, bulk antigen production using fermenters is possible using BHK21 cells which are anchorage independent.

For further details contact     

Department of Animal Biotechnology,
Madras Veterinary College,
Chennai-600 007